Introduction
After Alzheimer's disease (AD), Frontotemporal Lobar Degeneration (FTLD) is the second most common cause of dementia in the under 65s, accounting for 20% of cases [1] . It is a primary neurodegenerative disorder characterized by circumscribed neurodegeneration of the frontal and anterior temporal lobes. FTLD is clinically, pathologically and genetically, heterogeneous, and may in fact represent several distinct disorders united under this umbrella [1] .
In pathological terms, about half of cases can be defined by the presence of tauimmunoreactive changes in neurones, and sometimes glial cells, of the frontal and temporal cortex, and hippocampus, characterised by either neurofibrillary tangle-like structures or Pick bodies [2, 3] ; such cases have been designated as FTLD-tau [4] , and some are associated with mutations in the tau gene, MAPT [5] . Most of the remaining cases of FTLD are associated with varying combinations of inclusion bodies (neuronal cytoplasmic inclusions (NCI), dystrophic neurites (DN) and neuronal intranuclear inclusions (NII) within neurones of the same regions of cerebral cortex and hippocampus [2, 3] . These structures contain the transactive response (TAR) DNA binding protein with Mw 43kDa, TDP-43, [6, 7] , and such cases are termed FTLD-TDP [4] . Within the FTLD-TDP classification, four histological subtypes are recognised, and termed Types A to D according to the relative proportions of NCI, DN and NII [4] . About half of FTLD-TDP cases are associated with mutations in various genes, but chiefly as insertions/deletions in progranulin gene (GRN) [8, 9] , and most recently in C9ORF72 gene [10] [11] [12] , where an expansion of a hexanucleotide repeat within the first intron has now been identified as responsible for disease [10, 11] . Lastly, around 5% of cases are characterized by NCI containing fused in sarcoma protein (FUS) [13] , and are termed FTLD-FUS [4] .
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While to some extent there are some close clinical and pathological correlations (eg Semantic dementia (SD) and FTLD-TDP, type C, behavioural variant FTD (bvFTD) and Motor Neurone Disease (FTD+MND) and FTLD-TDP, type B) (see Neary et al [1] ), for the most part, and especially so with respect to patients with bvFTD) it is not possible to predict the underlying histology from clinical presentation alone. Genetic analysis can help as mutations in GRN and C9ORF72 predict FTLD-TDP histology [4, [9] [10] [11] [12] , with additional p62 immunoreactive changes within the cerebellum and hippocampus being characteristic of cases with C9ORF72 expansions [14] [15] [16] . MAPT mutations are always associated with an underlying tauopathy [5] , though this can adopt differing histological appearances, either Pick body-like [17] or neurofibrillary tangle-like [18] .
In order to develop rational therapeutic strategies for FTLD that seek to address or correct the underlying histological changes, it will obviously be necessary to be able to predict whether a case is FTLD-tau, FTLD-TDP or FTLD-FUS. As mentioned above, consistent clinicopathological correlations in SD and FTD+MND [1, 19] would direct a TDP-43 based therapy, as would genetic changes in GRN and C9ORF72 [8] [9] [10] [11] [12] . However, such a rationale would not be applicable for most cases of bvFTD where an underlying tau, TDP-43 or FUS histology is possible [4] , and if no identifiable gene is present, such cases could not be confidently differentiated on clinical assessment alone. A blood or cerebrospinal fluid based biomarker might be useful, though currently no such validated marker is available. PET imaging has been used to identify early cases of AD based on PIB binding to beta-amyloid plaques [20] , and although PET markers that might have the potential to indicate the presence of tau pathology are currently being evaluated [21] , there are no known equivalent pathologybased radioligands that could definitely identify the presence of, TDP-43 or FUS histology.
Over the last 10 years, it has become possible, using the PET ligand [11C](R)-PK11195, to image microglial activation, and this seems to correspond well to the distribution of the Accepted Article underlying pathological changes in Parkinson's disease and AD [22, 23] . Small pilot studies have also been successful in showing the presence of microglial activation in vivo in progressive supranuclear palsy (PSP) and cortical basal degeneration (CBD) [24, 25] , and also in a small cohort of FTLD patients [26] .
However, no correlative genetic or neuropathological data was available for any of these studies.
Given its heterogeneous pathology, it is possible that the different types of FTLD (ie FTLD- 
Patients and Methods

Patients
One hundred and four cases were investigated. All were obtained from the Manchester Brain [5, 8, 11] for methodological details).
The FTLD group was composed of 46 males and 32 females (see on-line Supplementatry Table 1 ). Forty three patients had been clinically diagnosed with bvFTD, 9 with FTD+MND, The 13 controls (6 males and 7 females) were judged to be clinically normal and none showed any pathology beyond that which might be anticipated for age. Three cases (over 65 years of age) showed mild deposition of amyloid beta protein, mostly in the form of diffuse amyloid plaques, one of which showed a mild neurofibrillary pathology confined essentially to the amygdala and hippocampal formation. Two other cases showed moderate cerebrovascular disease: the remaining 8 cases were apparently histologically normal. The 13 patients with AD all met pathological criteria for definite AD [31, 32] , and were Braak stage V or VI. All assessments were made by a single observer (SBL), blinded to diagnosis. Sections were scored twice to increase objectivity, and any discrepancies reconciled by consultation with a second observer (DMAM). In addition a random set of 8 sections were scored on a weekly basis over the course of the study.
Methods
Immunohistochemistry
Statistical Analysis
Rating data was entered into an excel spreadsheet and analysed using Statistical Package for Social Sciences (SPSS) software (version 17.0). A p-value of less than 0.05 was considered statistically significant. The data was subjected to testing for homogeneity, skewness and kurtosis. If any of these results were significant, the data was considered non-parametric and Kruskal-Wallis test was performed when 3 or more groups were analysed. If this detected any significant differences between the groups, post-hoc testing was performed to identify the groups between which significant differences existed. Mann-Whitney test was used to compare rating data between pairs of groups.
Results
Histological appearances
Both the phenotype and physiological function of microglial cells are highly plastic, relating to their level of activity. As such, microglial morphology depends upon the type and degree of pathology present, and on signalling from other cellular structures, such as surrounding As previously reported [33] , microglial cells were more common in cortical grey matter in AD compared to subcortical white matter, often clustered within and around amyloid plaques
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(not shown). In the control cases (Figure 1 ), activated microglial cells were largely absent, though a few were occasionally seen in respect to rare amyloid deposits. Ramified microglial cells were commonly seen in many of these cases.
Semiquantitative analyses
Scores for microglial cell 'severity' in cortical grey and subcortical white matter, of both frontal and temporal cortex, were compared separately across, and within, the different diagnostic groups.
Microglial cell scores were highly significantly different between FTLD (overall), AD and control groups for temporal cortical grey matter (F 2,103 =22.7; p<0.001) and frontal cortical white matter (F 2,104 =17.9; p<0.001), and marginally significant for temporal cortical white matter (F 2,103 =65.6; p=0.059) and frontal cortical grey matter (F 2,84 =6.4; p=0.042). Post hoc testing showed microglial scores were higher in FTLD than controls in all 4 regions (frontal cortical grey matter (p=0.022), temporal cortical grey matter (p=0.022), frontal cortical white matter (p=0.001) temporal cortical white matter (p=0.023)). Microglial scores were significantly higher in AD than controls in both frontal (p=0.019) and temporal (p<0.001) cortical grey matter, and also marginally so in temporal subcortical white matter (p=0.039), but not in frontal subcortical white matter (p=0.880). Moreover, microglial scores were significantly higher in frontal subcortical white matter in FTLD than in AD (p=0.002), but were higher in temporal cortical grey matter in AD than in FTLD (p<0.001). There were no significant differences in scores for AD and FTLD in either frontal cortical grey matter (p=0.609) or in temporal subcortical white matter (p=0.929).
The FTLD cases were stratified according to histological subtype (ie FTLD-tau, FTLD-TDP) and differences in microglial scores were sought between subgroups. Overall, there were no In the control group, there were no significant correlations between microglial cell scores in either frontal or temporal cortical grey or subcortical white matter and age at death.
Discussion
In the present study we have assessed and compared levels of microglial cell activation in frontal and temporal cortical grey and subcortical white matter regions in cases of FTLD and AD versus control subjects, and within FTLD cases alone have compared differed histological and genetic subtypes. As would be expected, we found higher levels of microglial cell activation than controls in all 4 regions in FTLD, and in 3 of the 4 regions studied in AD. Microglial cell activation was greater in frontal subcortical white matter in FTLD compared to AD, whereas it was higher in temporal cortical grey matter in AD compared to FTLD. Such observations emphasize the importance of neuroinflammation, both microglial and astrocytic in origin, in neurodegenerative disease [34] [35] [36] .
The patterns of microglial cell activation in FTLD and AD are likely to reflect the distribution of other pathologies, with the well known association between microglial cells and amyloid plaques, especially cored plaques [33] , leading to high cortical grey matter levels in AD compared to FTLD and controls, and the intense oligodendoglial tau pathology in subcortical white matter in FTLD cases associated with intronic mutations in exon 10 [18] .
When comparing FTLD cases, although levels of microglial cell activation were higher 'across the board' than in controls, no significant differences were noted when comparing is not associated with any inflammatory brain changes [40] . Hence, heterozygous GRN mutations in human FTLD, while directing PGRN haploinsufficiency, may not as shown here be associated with any (excessive) microglial cell activation, and that microgliosis here may derive indirectly from (products of) the neurodegenerative process involving neuronal cell death, rather than via a direct activation of microglial cells through PGRN deficiency.
Nonetheless, the present study suggests that high levels of microglial cell involvement in temporal lobe (subcortical white matter) might serve, at least, as a surrogate for that form of 
